title: Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancer.
abstract: The purpose of this study was to evaluate the tolerability of concurrent radiotherapy and cetuximab (bioradiotherapy [BRT]) after taxane-based induction chemotherapy in head and neck squamous cell carcinoma (HNSCC).
  
  
  
  One hundred four patients with HNSCC received BRT with (29%) or without (71%) prior taxane-based induction chemotherapy.
  
  
  
  Radiodermatitis (97%) and skin rash (65%) occurred frequently, but there was no difference of occurrence or the grade of the rash observed in the 2 populations. However, patients receiving taxane-based induction chemotherapy had a less severe rash as compared with patients without induction chemotherapy. Mucositis and dysphagia were frequent and comparable in the 2 groups. The occurrence of a skin rash (at any grade) did not predict an increased overall survival (OS) in the overall population, but it was associated with an improved 3-year OS in patients receiving taxane-based induction chemotherapy. OS was not influenced by the skin rash grade in the overall population of the 2 treatment subgroups.
  
  
  
  Taxane-based induction chemotherapy did not increase the rate of cetuximab-related toxicities. © 2015 Wiley Periodicals, Inc. Head Neck 38: E905-E910, 2016.
authors.affiliation: Department of Radiation Oncology, Gustave Roussy, Villejuif, Université Paris Sud, France.
authors.forename: Antonin
authors.initials: A
authors.lastname: Levy
authors.affiliation: Department of Radiation Oncology, Gustave Roussy, Villejuif, Université Paris Sud, France.
authors.forename: Francesca
authors.initials: F
authors.lastname: De Felice
authors.affiliation: Department of Radiation Oncology, Gustave Roussy, Villejuif, Université Paris Sud, France.
authors.forename: Sara
authors.initials: S
authors.lastname: Bellefqih
authors.affiliation: Department of Head and Neck Oncology, Gustave Roussy, Villejuif, France.|Centre Antoine Lacassagne, Nice, France.
authors.forename: Joël
authors.initials: J
authors.lastname: Guigay
authors.affiliation: Department of Radiation Oncology, Gustave Roussy, Villejuif, Université Paris Sud, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Deutsch
authors.affiliation: Department of Radiation Oncology, Gustave Roussy, Villejuif, Université Paris Sud, France.
authors.forename: France
authors.initials: F
authors.lastname: Nguyen
authors.affiliation: Department of Radiation Oncology, Gustave Roussy, Villejuif, Université Paris Sud, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Blanchard
authors.affiliation: Department of Radiation Oncology, Gustave Roussy, Villejuif, Université Paris Sud, France.
authors.forename: Yungan
authors.initials: Y
authors.lastname: Tao
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell; D000068818:Cetuximab / Q000009:adverse effects* / Q000627:therapeutic use; D059248:Chemoradiotherapy; D003680:Deglutition Disorders / Q000139:chemically induced; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D060828:Induction Chemotherapy; D008297:Male; D008875:Middle Aged; D052016:Mucositis / Q000139:chemically induced; D011855:Radiodermatitis / Q000473:pathology; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D043823:Taxoids; D000068818:Cetuximab
keywords: cetuximab; chemoradiotherapy; induction chemotherapy; toxicity